Table 3.
Transcatheter aortic valve implantation and bicuspid aortic valve: Published series to date (excluding the published data of a single case report)
| Author | Year | No. of cases | Country | Device | Access route | Prosthetic shape | Mean PG (mmHg) | AR (≥2+) | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
| Bauer52) | 2014 | 38 | Germany | ES:12 MCV:26 |
TF:31, TA:6 TAo:1 | N/A | 5.5 | 9 (25%) | N/A |
| Kochman57) | 2014 | 28 | Poland | ES:5 MCV:23 |
TF:22, TA:3 TS:2, TAo:1 | N/A | 10.3 | 6 (22%) | 11.4 |
| Costopoulos58) | 2014 | 21 | Italy | ES:8 MCV:13 |
TF:15, TA:1 TX:5 | N/A | 10.3 | 5 (24%) | 12 |
| Hayashida59) | 2013 | 21 | France | ES:11 MCV: 10 |
TF:13, TA:3 TAo:5 | Elliptical | 10.0 | 4 (19%) | more than 12 |
| Himbert54) | 2012 | 15 | France | MCV:15 | TF:14, TS:1 | Elliptical | 10.8 | Central: 1 PVL: 14* | 8 |
| Wijeshinghe53) | 2010 | 11 | Canada | ES: 11 | TF: 7, TA: 4 | Circular | 13.4 | 3 (27%) | 6.9 |
ES: Edwards SAPIEN; MCV: Medtronic core valve; TF: transfemoral; TA: transapical; TAo: transaortic; TS: transsubclavian; TX: transaxillary; N/A: not applicable. *Author did not state the degree of aortic valve regurgitation